Alkaline-Earth-Catalyzed sp3 C–H Functionalization of Methyl Azaarenes and Its Use in a One-Pot Four-Component Synthesis of Azaarenyl Benzylpyrazolones

Srinivasarao Yaragorla; Ravikrishna Dada; Garima Singh

doi:10.1055/s-0035-1560385

Synlett, Table of Contents

Synlett 2016; 27(06): 912-918
DOI: 10.1055/s-0035-1560385

letter

Alkaline-Earth-Catalyzed sp³ C–H Functionalization of Methyl Azaarenes and Its Use in a One-Pot Four-Component Synthesis of Azaarenyl Benzylpyrazolones

Authors

Srinivasarao Yaragorla*

Department of Chemistry, Central University of Rajasthan, Bandarsindri, NH-8, Ajmer District, Rajasthan, 305817, India Email: srinivasarao@curaj.ac.in Email: ysriict@gmail.com
Ravikrishna Dada

Department of Chemistry, Central University of Rajasthan, Bandarsindri, NH-8, Ajmer District, Rajasthan, 305817, India Email: srinivasarao@curaj.ac.in Email: ysriict@gmail.com
Garima Singh

Department of Chemistry, Central University of Rajasthan, Bandarsindri, NH-8, Ajmer District, Rajasthan, 305817, India Email: srinivasarao@curaj.ac.in Email: ysriict@gmail.com

Abstract

All articles of this category

Abstract

The sp³ C–H functionalization of methyl azaarenes by using calcium triflate as the catalyst is described, together with its use in the first synthesis of azaarenyl benzylpyrazolones by a one-pot four-component reaction.

Key words

nitrogen heterocycles - azaarenes - sp³ C–H functionalization - multicomponent reactions - pyrazolones

Full Text

References

References

For syntheses of methyl azaarenyl derivatives, see:

1a Komai H, Yoshino T, Matsunaga S, Kanai M. Org. Lett. 2011; 13: 1706
1b Rueping M, Tolstoluzhsky N. Org. Lett. 2011; 13: 1095
1c Qian B, Guo S, Shao J, Zhu Q, Yang L, Xia C, Huang H. J. Am. Chem. Soc. 2010; 132: 3650
1d Qian B, Xie P, Xie Y, Huang H. Org. Lett. 2011; 13: 2580
1e Yan Y, Xu K, Fang Y, Wang Z. J. Org. Chem. 2011; 76: 6849
1f Niu R, Yang S, Xiao J, Liang T, Li X. Cuihua Xuebao 2012; 33: 1636
1g Niu R, Xiao J, Liang T, Li X. Org. Lett. 2012; 14: 676
1h Lou S.-J, Xu D.-Q, Shen D.-F, Wang Y.-F, Liu Y.-K, Xu Z.-Y. Chem. Commun. 2012; 48: 11993
1i Jin J.-J, Niu H.-Y, Qu G.-R, Guo H.-M, Fossey JS. RSC Adv. 2012; 2: 5968
1j Meshram HM, Rao NN, Rao LC, Kumar SN. Tetrahedron Lett. 2012; 53: 3963
1k Mulla SA. R, Pathan MY, Chavan SS. RSC Adv. 2013; 3: 20281
1l Graves VB, Shaikh A. Tetrahedron Lett. 2013; 54: 695
1m Jin J, Wang D.-C, Niu H.-Y, Wu S, Qu G.-R, Zhang Z, Guo H. Tetrahedron 2013; 69: 6579
1n Rao NN, Meshram HM. Tetrahedron Lett. 2013; 54: 5087
1o Pi D, Jiang K, Zhou H, Sui Y, Uozumi Y, Zou K. RSC Adv. 2014; 4: 57875
1p Shao Z, Wang L, Xu L, Zhao H, Xiao J. RSC Adv. 2014; 4: 53188
1q Chatterjee S, Bhattacharjee P, Temburu J, Nandi D, Jaisankar P. Tetrahedron Lett. 2014; 55: 6680
1r Jiang K, Pi D, Zhou H, Liu S, Zou K. Tetrahedron 2014; 70: 3056
1s Blocker M, Immaneni S, Shaikh A. Tetrahedron Lett. 2014; 55: 5572
1t Kumar NS, Rao LC, JagadeeshBabu N, Kumar VD, Murthy US. N, Meshram HM. Synlett 2015; 26: 1808
1u Jamal Z, Teo Y.-C. RSC Adv. 2015; 5: 26949
1v Hao S.-H, Zhang X.-Y, Dong D.-Q, Wang Z.-L. Chin. Chem. Lett. 2015; 26: 599
1w Kumar A, Shukla RD. Green Chem. 2015; 17: 848
1x Obora Y, Ogawa S, Yamamoto N. J. Org. Chem. 2012; 77: 9429
1y Xu L, Shao Z, Wang L, Zhao H, Xiao J. Tetrahedron Lett. 2012; 55: 6856
1z Jamal Z, Teo Y.-C. Synlett 2014; 25: 2049
1aa Li VM, Gavrishova TN, Budyka MF. Russ. J. Org. Chem. 2012; 48: 823

2a Mekouar K, Mouscadet JF, Desmaële D, Subra F, Leh H, Savouré D, Auclair C, Angelo J. J. Med. Chem. 1998; 41: 2846
2b Fournet A, Mahieux R, Fakhfakh MA, Franck X, Hocquemiller R, Figadère B. Bioorg. Med. Chem. Lett. 2003; 13: 891
2c Fakhfakh MA, Fournet A, Prina E, Mouscadet J.-F, Franck X, Hocquemiller R, Figadère B. Bioorg. Med. Chem. 2003; 11: 5013

3a Bayle MN, Bénard C, Zouhiri F, Mouscadet J.-F, Leh H, Thomas C.-M, Mbemba G, Desmaële D, d’Angelo J. Bioorg. Med. Chem. Lett. 2005; 15: 4019
3b Bénard C, Zouhiri F, Normand-Bayle M, Danet M, Desmaële D, Leh H, Mouscadet J.-F, Mbemba G, Thomas C.-M, Bonnenfant S, Le Bret M, d’Angelo J. Bioorg. Med. Chem. 2004; 14: 2473

4a Harrington PJ. Pharmaceutical Process Chemistry for Synthesis: Rethinking the Routes to Scale-Up. Wiley; Oxford: 2011. Chap. 6, 164
4b Young RN In Case Studies in Modern Drug Discovery and Development . Huang X, Aslanian RG. Wiley; Hoboken: 2012. Chap. 8, 154

5 Michael JP. Nat. Prod. Rep. 2005; 22: 627
6 Zwaagstra ME, Schoenmakers SH. H. F, Nederkoorn PH. J, Gelens E, Timmerman H, Zhang M.-Q. J. Med. Chem. 1998; 41: 1439

7a Zamboni R, Belley M, Champion E, Charette L, DeHaven R, Frenette R, Gauthier JY, Jones TR, Leger S, Masson P, McFarlane CS, Metters K, Pong SS, Piechuta H, Rokach J, Thérien M, Williams HW. R, Young RN. J. Med. Chem. 1992; 35: 3832
7b King A, Corley EG, Anderson RK, Larsen RD, Verhoeven TR, Reider PJ, Xiang YB, Belley M, Leblanc Y. J. Org. Chem. 1993; 58: 3731
7c McNamara JM, Leazer JL, Bhupathy M, Amato JS, Reamer RA, Reider PJ, Grabowski EJ. J. J. Org. Chem. 1989; 54: 3718

8 Merschaert A, Boquel P, Van Hoeck J.-P, Gorissen H, Borghese A, Bonnier B, Mockel A, Napora F. Org. Process Res. Dev. 2006; 10: 776

9a Felpin F.-X, Lebreton J. Eur. J. Org. Chem. 2003; 3693
9b Carey JS, Laffan L, Thompson C, Williams MT. Org. Biomol. Chem. 2006; 4: 2337

10a Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, Ebner H, Ebner C. J. Allergy Clin. Immunol. 2003; 111: 882
10b Watanabe T, Yuki S, Egawa M, Nishi H. J. Pharmacol. Exp. Ther. 1994; 268: 1597
10c Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito KI. J. Pharmacol. Exp. Ther. 1997; 281: 921
10d Wu TW, Zeng LH, Wu J, Fung KP. Life Sci. 2002; 71: 2249
10e Al-Haiza MA, El-Assiery SA, Sayed GH. Acta Pharm. (Zagreb, Croatia) 2001; 51: 251
10f Castagnolo D, Manetti F, Radi M, Bechi B, Pagano M, De Logu A, Meleddu R, Saddi M, Botta M. Bioorg. Med. Chem. 2009; 17: 5716
10g Radi M, Bernardo V, Bechi B, Castagnolo D, Pagano M, Botta M. Tetrahedron Lett. 2009; 50: 6572
10h Moreau F, Desroy N, Genevard JM, Vongsouthi V, Gerusz V, Le Fralliec G, Oliveira C, Floquet S, Denis A, Escaich S, Wolf K, Busemann M, Aschenbsenner A. Bioorg. Med. Chem. Lett. 2008; 18: 4022
10i Badawey EA. M, El-Ashmawey IM. Eur. J. Med. Chem. 1998; 33: 349
10j Pasha FA, Muddassar M, Neaz MM, Cho SJ. J. Mol. Graphics Modell. 2009; 28: 54
10k Rosiere CE, Grossman MI. Science 1951; 113: 651
10l Bailey DM, Hansen PE, Hlavac AG, Baizman ER, Pearl J, Defelice AF, Feigenson ME. J. Med. Chem. 1985; 28: 256
10m Chauhan PM. S, Singh S, Chatterjee RK. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 1993; 32: 858
10n Gunasekaran P, Perumal S, Yogeeswari P, Sriram D. Eur. J. Med. Chem. 2011; 46: 4530

11a Dömling A, Ugi I. Angew. Chem. Int. Ed. 2000; 39: 3168
11b Rotstein BH, Zaretsky S, Rai V, Yudin AK. Chem. Rev. 2014; 114: 8323

12a Simon M.-O, Li C.-J. Chem. Soc. Rev. 2012; 41: 1415
12b Jessop PG. Green Chem. 2011; 13: 1391

13a Forkel NV, Henderson DA, Fuchter MJ. Green Chem. 2012; 14: 2129
13b Arrowsmith M, Shepherd WM. S, Hill MS, Kociok-Köhn G. Chem. Commun. 2014; 50: 12676
13c Crimmin MR, Casely IJ, Hill MS. J. Am. Chem. Soc. 2005; 127: 2042
13d Begouin J, Niggemann M. Chem. Eur. J. 2013; 19: 8030
13e Niggemann M, Meel MJ. Angew. Chem. Int. Ed. 2010; 49: 3684

14a Yaragorla S, Pareek A, Dada R. Tetrahedron Lett. 2015; 56: 4770
14b Yaragorla S, Saini PL, Singh G. Tetrahedron Lett. 2015; 56: 1649
14c Yaragorla S, Singh G, Saini P, Reddy MK. Tetrahedron Lett. 2014; 55: 4657
14d Yaragorla S, Sudhakar A, Kiranmai N. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2014; 53: 1471
14e Yaragorla S, Kumar GS. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem. 2015; 54: 240

15 2-Aryl-4-(1-Aryl-2-hetarylethyl)-5-methyl-1,2-dihydro-3H-pyrazol-3-ones 5a–u; General Procedure Ca(OTf)₂ (10 mol%) was added to a stirred solution of MeCOCO₂Et (1.13 mmol), arylhydrazine 3 (0.942 mmol), aryl aldehyde 2 (0.934 mmol), and 2-methylazarene 1 (0.942 mmol) in H₂O (3 mL), and the mixture was heated to 100 °C. When the reaction was complete (TLC; ~5 h), the mixture was extracted with EtOAc (3 × 5 mL). The combined organic layers were dried (Na₂SO₄), filtered, and concentrated to give a crude solid that was purified by column chromatography. 5-Methyl-2-phenyl-4-(1-phenyl-2-quinolin-2-ylethyl)-1,2-dihydro-3H-pyrazol-3-one (5a) Pink solid; yield: 227.9 mg (80%); mp 67–68 °C. ¹H NMR (500 MHz, CDCl₃): δ = 7.97 (t, J = 9 Hz, 2 H), 7.83 (d, J = 7.5 Hz, 2 H), 7.69–7.62 (m, 2 H), 7.63 (t, J = 7 Hz, 1 H), 7.44 (t, J = 7 Hz, 2 H), 7.17–7.02 (m, 7 H), 4.32 (d, J = 9 Hz, 1 H), 3.77 (dd, J = 2, 13.5 Hz, 1 H), 3.76 (t, J = 13.5 Hz, 1 H), 1.72 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ = 160.3, 148.5, 144.8, 144.3, 139.6, 138.3, 132.7, 130.6, 129.1 (2C), 128.6 (2C), 128.4, 127.8, 127.7 (2C), 126.8, 126.4, 126.2, 125.1, 122.9, 121.8 (2C), 100.8, 42.7, 42.1, 13.4. 4-[2-(7-Chloroquinolin-2-yl)-1-(4-nitrophenyl)ethyl]-5-methyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one (5m) Brown solid; yield: 222.7 mg (78%); mp 105–106 °C. ¹H NMR (500 MHz, CDCl₃): δ = 8.01–7.95 (m, 4 H), 7.8 (d, J = 7.5 Hz, 2 H), 7.66 (d, J = 8.5 Hz, 1 H), 7.45–7.38 (m, 3 H), 7.26 (d, J = 7.5 Hz, 2 H), 7.21–7.18 (m, 1 H), 7.06 (d, J = 8.5 Hz, 1 H), 4.48 (d, J = 9.5 Hz, 1 H), 3.77 (t, J = 13.5 Hz, 1 H), 3.66 (dd, J = 2.5, 14.0 Hz, 1 H), 1.74 (s, 3 H). ¹³C NMR (125 MHz, CDCl₃): δ = 160.3, 151.5, 150.7, 147.9, 146.5, 145.3, 139.2, 138.5, 137.2, 129.0, 128.8, 128.6, 128.4, 125.6, 125.5, 125.2, 123.7, 122.9, 122.0, 99.4, 42.0, 41.4, 13.3.